Norgine is a prominent European specialist pharmaceutical company that has been dedicated to improving patients' lives for over a century. Their unwavering commitment to transformative medicine is at the core of their operations. Leveraging their extensive European experience, integrated infrastructure, and collaborative partnership approach, Norgine swiftly develops creative solutions to provide patients with life-changing medications that may otherwise be inaccessible. In 2021 alone, Norgine proudly assisted 24 million patients worldwide, achieving a remarkable €505 million in net product sales, representing a growth of 10% compared to the previous year.
With a direct presence in 16 European countries, as well as Australia and New Zealand, Norgine possesses a broad international footprint. In addition, they have established a robust global network of partnerships in non-Norgine markets. Norgine distinguishes itself as a flexible and fully integrated pharmaceutical enterprise. In addition to their sales and marketing infrastructure, they have manufacturing facilities in Hengoed, Wales, and Dreux, France, as well as third-party supply networks and substantial product development capabilities. This comprehensive setup empowers Norgine to acquire, develop, and commercialize specialized and innovative products that significantly impact the lives of patients worldwide.
Recognizing the need to support the advancement of healthcare, Norgine established Norgine Ventures in 2012. This complementary business unit offers debt-like financing to innovative healthcare companies across Europe and the United States, providing crucial support to drive progress and breakthroughs in the industry. Through their multifaceted approach, Norgine is dedicated to making a positive difference in the healthcare sector and enhancing the well-being of patients globally.